PRTN3 and alpha 1-antitrypsin deficiency: Using this immunoassay that detects the footprint of PR3 activity, we provide evidence that in AATD patients a single dose of 240 mg/kg AAT results in a marked transient reduction in PR3 activity, reaching levels of non-smoking AAT sufficient controls.